# Moderna Stock Surges Past AI Giants

> Moderna's stock has crushed Nvidia, Micron, and Sandisk with 600% gains this year, now in Nasdaq-100.
- Title: Moderna Stock Surges Past AI Giants · The Motley Fool
- Summary: Moderna's stock has crushed Nvidia, Micron, and Sandisk with 600% gains this year, now in Nasdaq-100. Moderna's stock surged over 600% this year, surpassing…
- Keywords: moderna, nasdaq-100, nvidia, micron, sandisk, ai stocks, oncology treatments, finance, money, Stock, Surges, Past
- Source: The Motley Fool — https://fool.com/investing/2026/10/16/meet-the-new-nasdaq-100-stock-that-s-crushing-nvidia-micron-and-sandisk-is-it-too-late-to-buy
- Author: Adria Cimino
- Published: 2026-10-16T11:05:02+00:00
- Read time: 1 min
- Topics: moderna, nasdaq-100, nvidia, micron, sandisk, ai stocks, oncology treatments, finance, money
## Moderna's 600% surge
Moderna's stock surged over 600% this year, outperforming Nvidia, Micron, and Sandisk.
## Nasdaq-100 entry
Moderna entered the Nasdaq-100 index this year, tracking the biggest non-financial Nasdaq companies.
## Coronavirus vaccine success
Moderna's coronavirus vaccine generated over $18 billion in revenue at its peak in 2022.
## Recent challenges
Moderna faced declining vaccine demand, RSV vaccine struggles, and a failed CMV vaccine candidate.
## Oncology breakthrough
Moderna's intismeran autogene vaccine showed success in melanoma patients with recurrence-free survival.
## Price target surpassing
Moderna's stock price of $225 surpasses Wall Street's average 12-month price estimate of $122.
## Buy recommendation
Moderna has room to grow as it wins approval for oncology treatments and generates new revenue streams.

> Moderna is transforming into a larger biotech company with the ability to address a broad range of treatment areas.
## Key takeaway

Moderna's stock surged over 600% this year, surpassing AI stocks and Wall Street price targets as it advances into oncology treatments.